期刊文献+

多发性骨髓瘤患者血清lncRNA HOTAIR表达量与血清β_2微球蛋白及预后的相关性 被引量:15

The correlation between serum lncRNA HOTAIR expression level,serum beta2-microglobulin and prognosis in patients with multiple myeloma
下载PDF
导出
摘要 目的分析多发性骨髓瘤(MM)患者血清长链非编码RNA(lncRNA)HOTAIR表达量与血清β_2微球蛋白(β_2-MG)及预后的相关性。方法选取100例MM患者作为病例组,根据化疗治疗效果将其分为有效组(74例)和无效组(26例),选取50例健康志愿者作为对照组。对各组研究对象的血清lncRNA HOTAIR水平、β_2-MG水平进行检测和比较;对病例组患者进行随访,对患者的总生存期(OS)和无疾病进展生存期(PFS)进行观察和比较。结果病例组患者的血清lncRNA HOTAIR水平和β_2-MG水平均显著高于对照组,无效组的血清lncRNA HOTAIR水平和β_2-MG水平均显著高于有效组,差异均有统计学意义(t=18.445、45.023、16.212、22.679,P<0.05);病例组患者及有效组、无效组患者的血清lncRNA HOTAIR水平均与β_2-MG水平具有相关性(r=0.880、0.695、0.893,P<0.05);血清lncRNA HOTAIR水平和β_2-MG水平较高患者的OS、PFS均显著低于血清lncRNA HOTAIR和β_2-MG水平较低的患者,差异均有统计学意义(χ~2=39.435、37.371、38.054、34.696,P<0.05)。结论 MM患者表现为血清lncRNA HOTAIR水平的升高,其水平与β_2-MG水平具有密切的相关性,而且这两种血清标志物水平与化疗药物的治疗效果和生存期有关,可作为评价治疗效果和预测预后的辅助指标。 Objective To analyze the correlation between serum long chain non encoding RNA(lncRNA)HOTAIR expression level,serum beta2-microglobulin(β2-MG)and prognosis in patients with multiple myeloma(MM).Methods 100 cases of MM patients were selected as the case group and divided into the efficient group(74 cases)and the unefficient group(26 cases)according to the therapeutic effects of chemotherapy.50 healthy volunteers were selected as the control group.The serum lncRNA HOTAIR and β2-MG levels of the objects in each group were detected and compared.The patients in the case group were followed up,the overall survival(OS)and the progression free survival(PFS)of the patients were observed and compared.Results The serum lncRNA HOTAIR andβ2-MG levels of the patients in the case group were significantly higher than those in the control group,the serum lncRNA HOTAIR and β2-MG levels of the patients in the unefficient group were significantly higher than those in the efficient group,the differences were statistically significant(t=18.445,45.023,16.212,22.679,P〈0.5);The serum lncRNA HOTAIR level was correlated with theβ2-MG level of the patients in the case group,the efficient group or the unefficient group(r=0.880,0.695,0.893,P〈0.5);OS,PFS of the patients with high level of serum lncRNA HOTAIR orβ2-MG level were higher in patients with low level of serum lncRNA HOTAIR or β2-MG level,the differences were statistically significant(χ^2=39.435,37.371,38.054,34.696,P〈0.5).Conclusion MM patients show elevated level of serum lncRNA HOTAIR and the level has a close correlation withβ2-MG level.Meanwhile,the levels of two serum markers are correlated with the therapeutic effects of chemotherapeutic agents and the survival of the patients,can be used as assistant indexes to evaluate the therapeutic effects and the prognosis.
出处 《中国实验诊断学》 2018年第2期191-196,共6页 Chinese Journal of Laboratory Diagnosis
基金 国家自然科学基金资助项目(81471165)
关键词 多发性骨髓瘤 血清 长链非编码RNA Β2微球蛋白 预后 multiple myeloma serum long chain non coding RNA beta2-microglobulin prognosis
  • 相关文献

参考文献7

二级参考文献75

  • 1王晓梅,侯健,周帆.蛋白酶体抑制剂bortezomib治疗多发性骨髓瘤的作用机制和临床试验[J].白血病.淋巴瘤,2006,15(4):296-298. 被引量:2
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007 [ J ]. CA Cancer J Clin ,2007,57( 1 ) :43 -60.
  • 3Sirohi B ,Powles R. Multiple myeloma[J]. Lancet,2004,363(4) :875 -887.
  • 4Creipp PR, Lust IA, O'Fallon Mu, a al. Plasmal cell Labelling index and betd 1-microglobulin predict sufinual independent af thymidine Rinase and C-reactive protein in multiple myeloma [ J ]. Blood, 1993,81 (9) ,3382 - 3387.
  • 5Alexandrakis MG, Passam FH, Ganotakis ES, et al. The cliniealand prognostic significance of erythrocyte sedimentation rate( ESR), serum interleukin- 6 ( IL- 6 ) and acute phase protein levelsin multiple myeloma[ J ]. Clin Lab Haematol, 2003,25 ( 1 ) :41 - 46.
  • 6Korde N,Zingone A,Kwok ML,et al.Phase Ⅱ clinical and correlative study of carfilzomib,lenalidomide,and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiplemyeloma (MM) Patients[J].Blood,2013,122(21):538.
  • 7Paiva B,Corchete LA,Gutierrez N,et al.Phenotypic and genomic analysis of multiple myeloma (MM) minimal residual disease (MRD) clonal plasma cells (PCs)[J].Blood,2013,122(21):402.
  • 8Paino T,Paiva B,Sayagués JM,et al.Phenotypic identification of subclones in multiple myeloma with different genomic profile,clonogenic potential and drug sensitivity[J].Blood,2013,122 (21):531.
  • 9Ferrero S,Ladetto M,Drandi D,et al.Long term molecular results of the Gimema VEL-03-096 trial:molecular remission achievement and loss are major outcome predictors[J].Blood,2013,122(21):2077.
  • 10Martinez Lopez J,Laheurt J J,Pepin F,et al.Prognostic value of deep sequencing approach for minimal residual disease (MRD)detection in multiple myeloma patients[J].Blood,2013,122(21):1848.

共引文献83

同被引文献98

引证文献15

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部